DE69233774D1 - Prüfung und Modell für Alzheimers-Krankheit - Google Patents

Prüfung und Modell für Alzheimers-Krankheit

Info

Publication number: DE69233774D1
Authority: DE; Germany
Prior art keywords: amino acid; model; exam; disease; alzheimer
Prior art date: 1991-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69233774T

Other languages

English (en)

Inventor

John Anthony Hardy

Marie-Christine Chartier-Harlin

Alison Mary Goate

Michael John Owen

Michael John Mullan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Elan Pharmaceuticals LLC

Original Assignee

Elan Pharmaceuticals LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-21

Filing date

1992-01-21

Publication date

2009-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233774(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-01-21 Priority claimed from GB919101307A external-priority patent/GB9101307D0/en

1991-08-28 Priority claimed from GB919118445A external-priority patent/GB9118445D0/en

1992-01-21 Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC

2009-12-10 Application granted granted Critical

2009-12-10 Publication of DE69233774D1 publication Critical patent/DE69233774D1/de

2012-01-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

DE69233774T 1991-01-21 1992-01-21 Prüfung und Modell für Alzheimers-Krankheit Expired - Lifetime DE69233774D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919101307A GB9101307D0 (en)	1991-01-21	1991-01-21	Test for alzheimers disease
GB919118445A GB9118445D0 (en)	1991-08-28	1991-08-28	Test for alzheimer's disease

Publications (1)

Publication Number	Publication Date
DE69233774D1 true DE69233774D1 (de)	2009-12-10

Family

ID=26298303

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE69233774T Expired - Lifetime DE69233774D1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69233468T Expired - Lifetime DE69233468T3 (de)	1991-01-21	1992-01-21	Prüfung und modell für alzheimers-krankheit
DE0971033T Pending DE971033T1 (de)	1991-01-21	1992-01-21	Prüfung und Modell für Alzheimers-Krankheit

Country Status (10)

Country	Link
US (3)	US5877015A (de)
EP (2)	EP0971033B1 (de)
JP (3)	JP3510244B2 (de)
AT (2)	ATE447016T1 (de)
AU (1)	AU652997B2 (de)
CA (2)	CA2372251A1 (de)
DE (3)	DE69233774D1 (de)
DK (2)	DK0568575T4 (de)
ES (2)	ES2335720T3 (de)
WO (1)	WO1992013069A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69233774D1 (de)	1991-01-21	2009-12-10	Elan Pharm Inc	Prüfung und Modell für Alzheimers-Krankheit
US5705401A (en) *	1991-11-12	1998-01-06	The University Of Melbourne	Method of assaying for alzheimer's disease
WO1993013114A1 (en)	1991-12-24	1993-07-08	Isis Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US5604131A (en) *	1992-01-07	1997-02-18	Athena Neurosciences, Inc.	cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
PT620849E (pt) *	1992-01-07	2003-11-28	Elan Pharm Inc	Modelos animais transgenicos para a doenca de alzheimer
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en)	1993-06-17	2003-08-26	Brigham And Women's Hospital	Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) *	1993-01-22	2001-12-11	Ludwig Institute For Cancer Research	MAGE-1 derived nona peptides, and compositions thereof
ES2155099T3 (es) *	1993-10-27	2001-05-01	Elan Pharm Inc	Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en)	1994-01-27	1995-08-03	Karen Hsiao	Transgenic non-human mammals with progressive neurologic disease
CA2198451A1 (en) *	1994-09-01	1996-03-07	Gurparkash Singh	Transgenic animal expressing a familial form of human amyloid precursor protein
US6187992B1 (en)	1994-12-05	2001-02-13	Merck & Co., Inc.	Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) *	1994-12-06	1997-10-07	Rothenberg; Barry E.	Methods to identify hemochromatosis
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
CA2221986A1 (en) *	1995-06-07	1996-12-19	Athena Neurosciences, Inc.	Method for identifying alzheimer's disease therapeutics using transgenic animal models
AUPN649395A0 (en) *	1995-11-10	1995-12-07	Ramsay Health Care Pty Ltd	A method for diagnosing alzheimer's disease
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
CA2183901A1 (en) *	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) *	1998-05-22	2005-08-23	Nanoproducts Corporation	Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) *	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (es) *	1997-06-04	2000-03-01	Euroespes S A	Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer.
CN100429230C (zh) *	1997-10-24	2008-10-29	阿文蒂斯药物股份有限公司	能抑制早老素和β-淀粉样肽或其前体间相互作用的肽
FR2770217B1 (fr) *	1997-10-24	2001-12-07	Rhone Poulenc Rorer Sa	Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide
US6743427B1 (en)	1997-12-02	2004-06-01	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6844148B1 (en)	1998-09-24	2005-01-18	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) *	1998-09-24	2004-11-25	Gurney Mark E.	Alzheimer's disease secretase, app substrates therefor, and uses therefor
EP1115874B1 (de)	1998-09-24	2009-01-07	Pharmacia & Upjohn Company LLC	Alzheimersche krankheit sekretase
US6699671B1 (en)	1998-09-24	2004-03-02	Pharmacia & Upjohn Company	Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en)	1998-12-31	2008-11-25	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US7115410B1 (en)	1999-02-10	2006-10-03	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
GB2364059B (en)	1999-02-10	2004-01-14	Elan Pharm Inc	Beta-Secretase enzyme compositions and methods
US6355425B1 (en)	1999-03-26	2002-03-12	Billups-Rothenberg, Inc.	Mutations associated with iron disorders
US7056661B2 (en) *	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US20090162883A1 (en) *	1999-09-23	2009-06-25	Pharmacia & Upjohn Company	Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en)	1999-12-02	2009-04-07	Elan Pharmaceuticals, Inc.	β-secretase enzyme compositions and methods
US6310048B1 (en)	1999-12-09	2001-10-30	St. Louis University	Antisense modulation of amyloid beta protein expression
WO2001047944A2 (en) *	1999-12-28	2001-07-05	Curagen Corporation	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE60124080T2 (de)	2000-03-23	2007-03-01	Elan Pharmaceuticals, Inc., San Francisco	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
JP2004502664A (ja) *	2000-06-30	2004-01-29	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病処置用化合物
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
EP1666452A2 (de)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Verbindungen zur Behandlung der Alzheimerischen Krankheit
WO2002002769A1 (en) *	2000-07-06	2002-01-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	A novel app mutation associated with an unusual alzheimer's disease pathology
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
ATE396174T1 (de) *	2001-06-01	2008-06-15	Elan Pharm Inc	Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MXPA03011521A (es)	2001-06-13	2004-03-18	Elan Pharm Inc	Aminadioles para tratamiento de enfermedad de alzheimer.
US6982264B2 (en) *	2001-06-27	2006-01-03	Elan Pharmaceuticals, Inc.	Substituted alcohols useful in treatment of Alzheimer's disease
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
US7067542B2 (en) *	2001-07-10	2006-06-27	Pharmacia & Upjohn Company	Diaminediols for the treatment of Alzheimer's disease
CA2453451A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Aminediols for the treatment of alzheimer's disease
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
BR0213139A (pt)	2001-10-04	2004-08-10	Elan Pharm Inc	Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
NZ533107A (en) *	2001-11-08	2007-04-27	Upjohn Co	N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003043618A2 (en) *	2001-11-19	2003-05-30	Elan Pharmaceuticals, Inc.	Amino diols useful in the treatment of alzheimer's disease
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
AU2003216370A1 (en) *	2002-02-27	2003-09-09	Merck And Co., Inc.	Assays to monitor amyloid precursor protein processing
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) *	2002-04-30	2004-07-15	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
AU2003293155A1 (en) *	2002-11-27	2004-06-23	Elan Pharmaceutical, Inc.	Substituted ureas and carbamates
US20060188512A1 (en)	2003-02-01	2006-08-24	Ted Yednock	Active immunization to generate antibodies to solble a-beta
CA2522805A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
EP1615892A2 (de) *	2003-04-21	2006-01-18	Elan Pharmaceuticals, Inc.	Benzamid-2-hydroxy-3-diaminoalkane
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) *	2003-07-08	2005-01-13	Xiao-Jia Chang	Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) *	2003-07-31	2005-02-03	Pfizer Products Inc.	Bsep polypeptide variants and uses thereof
US20060014790A1 (en) *	2004-01-21	2006-01-19	Varghese John	Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2005087751A2 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
CA2556826A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087215A1 (en)	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP2007538024A (ja) *	2004-05-19	2007-12-27	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
JP2008505929A (ja) *	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7385085B2 (en) *	2004-07-09	2008-06-10	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) *	2004-08-27	2006-03-09	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
MX2007005317A (es) *	2004-11-05	2007-06-11	Wyeth Corp	Modalidades de formacion de imagen para seleccionar agentes terapeuticos para la enfermedad de alzheimer.
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
EP2332408B1 (de)	2005-02-17	2013-11-13	Biogen Idec MA Inc.	Behandlung neurologischer Störungen
JP4853892B2 (ja) *	2005-04-13	2012-01-11	独立行政法人国立精神・神経医療研究センター	変異対立遺伝子に対する特異的なＲＮＡｉの評価方法
JP5339901B2 (ja)	2005-05-10	2013-11-13	バイオジェン・アイデック・エムエイ・インコーポレイテッド	炎症傷害の処置および評価
GB0511861D0 (en) *	2005-06-13	2005-07-20	Merck Sharp & Dohme	Proteins
EP1746092A1 (de)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
US20080293680A1 (en) *	2005-08-03	2008-11-27	Stefan Peters	Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
EP1915353A2 (de) *	2005-08-11	2008-04-30	Boehringer Ingelheim International GmbH	Isophthalsäurediamide zur behandlung der alzheimer erkrankung
CA2618013A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Beta-secretase inhibitors for use in the treatment of alzheimer's disease
US20100144681A1 (en) *	2005-08-11	2010-06-10	Klaus Fuchs	Compounds for the treatment of alzheimer's disease
CA2618019A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Compounds for the treatment of alzheimer's disease
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
EP1937638A1 (de) *	2005-10-12	2008-07-02	Elan Pharmaceuticals Inc.	Verfahren zur behandlung von amyloidose unter verwendung von aspartylproteaseinhibitor- arylcyclopropylderivaten
US7776882B2 (en) *	2006-02-06	2010-08-17	Baxter Ellen W	2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en)	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8357781B2 (en)	2006-06-01	2013-01-22	Janssen Alzheimer Immunotherapy	Neuroactive fragments of APP
CA2657248C (en)	2006-07-13	2018-10-30	Wyeth	Production of glycoproteins
EP2862581B1 (de)	2006-10-12	2021-08-11	BHI Limited Partnership	Verfahren, Verbindungen, Zusammensetzungen und Medien zur Abgabe von 3-Amino-1-Propanesulfonsäure
CA2666317C (en)	2006-11-03	2013-08-06	Wyeth	Glycolysis-inhibiting substances in cell culture
ES2541454T3 (es)	2007-03-02	2015-07-20	Wyeth Llc	Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
US8466118B2 (en) *	2007-04-23	2013-06-18	Saint Louis University	Modulation of blood brain barrier protein expression
KR101461659B1 (ko)	2007-05-11	2014-11-17	토마스 제퍼슨 유니버시티	신경변성 질환 및 장애의 치료 및 예방 방법
WO2009007300A2 (en)	2007-07-06	2009-01-15	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
BRPI0906625A2 (pt) *	2008-01-28	2015-07-14	Janssen Pharmaceutica Nv	Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
NZ586830A (en) *	2008-01-29	2012-02-24	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
US20110166197A1 (en) *	2008-02-19	2011-07-07	Edunn Biotechnology, Inc.	Antisense Modulation Of Amyloid Beta Protein Expression
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
MX353096B (es)	2010-08-19	2017-12-19	Buck Institute For Age Res Star	Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
AU2013235422B2 (en)	2012-03-19	2016-12-15	Buck Institute For Research On Aging	APP specific BACE inhibitors (ASBIs) and uses thereof
HUE035607T2 (en)	2012-06-25	2018-05-28	Brigham & Womens Hospital Inc	Targeted therapeutic agents
JP6471100B2 (ja)	2013-02-12	2019-02-13	バック・インスティテュート・フォー・リサーチ・オン・エイジング	Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
EP2978446B1 (de)	2013-03-27	2020-03-04	The General Hospital Corporation	Anti-cd33 antikörper zur behandlung von morbus alzheimer
KR101890978B1 (ko)	2014-06-17	2018-08-24	서울대학교산학협력단	알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
EP3626832A3 (de)	2014-11-25	2020-05-13	The Brigham and Women's Hospital, Inc.	Verfahren zur identifizierung und behandlung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
US10683552B2 (en)	2014-11-25	2020-06-16	Presidents And Fellows Of Harvard College	Clonal haematopoiesis
AU2016311502B2 (en)	2015-08-27	2019-07-18	Nantneuro, Llc	Compositions for app-selective bace inhibition and uses therfor
CN109563089B (zh)	2016-05-12	2023-06-16	巴克老年研究所	促进app正常加工的化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) *	1983-04-19	1985-01-08	The Wistar Institute Of Anatomy And Biology	HLA D Typing assay
JPS6147500A (ja) *	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja) *	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) *	1985-10-28	1987-05-09	Teijin Ltd	遺伝子断片およびプラスミド
AU606320B2 (en) *	1985-11-01	1991-02-07	International Genetic Engineering, Inc.	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
AU3056289A (en) *	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) *	1988-03-22	1992-07-28	Cornell Research Foundation, Inc.	Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (de)	1989-03-09	1990-09-13	Bayer Ag	Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
WO1990013641A1 (en)	1989-05-10	1990-11-15	Sloan-Kettering Institute For Cancer Research	Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
WO1991004753A1 (en)	1989-10-02	1991-04-18	Cetus Corporation	Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en)	1989-12-22	1993-01-19	The Trustees Of Columbia University In The City Of New York	Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (de) *	1990-04-10	1991-10-16	Miles Inc.	Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
EP0527823A1 (de) *	1990-04-24	1993-02-24	The Regents Of The University Of California	Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2
ATE260974T1 (de) *	1990-06-15	2004-03-15	Scios Inc	Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
WO1992000521A1 (en) *	1990-06-29	1992-01-09	Case Western Reserve University	Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) *	1990-11-27	1992-02-25	Will L F & Cie Sa	Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
DE69233774D1 (de)	1991-01-21	2009-12-10	Elan Pharm Inc	Prüfung und Modell für Alzheimers-Krankheit
AU2765992A (en) *	1991-10-03	1993-05-03	Indiana University Foundation	Method for screening for alzheimer's disease
PT620849E (pt) *	1992-01-07	2003-11-28	Elan Pharm Inc	Modelos animais transgenicos para a doenca de alzheimer
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en)	2005-04-27	2008-05-13	Samtec, Inc.	Elevated height electrical connector

1992
- 1992-01-21 DE DE69233774T patent/DE69233774D1/de not_active Expired - Lifetime
- 1992-01-21 US US08/104,165 patent/US5877015A/en not_active Expired - Lifetime
- 1992-01-21 DK DK92903304.1T patent/DK0568575T4/da active
- 1992-01-21 EP EP99109196A patent/EP0971033B1/de not_active Revoked
- 1992-01-21 AU AU11694/92A patent/AU652997B2/en not_active Expired
- 1992-01-21 JP JP50357592A patent/JP3510244B2/ja not_active Expired - Lifetime
- 1992-01-21 DK DK99109196T patent/DK0971033T3/da active
- 1992-01-21 DE DE69233468T patent/DE69233468T3/de not_active Expired - Lifetime
- 1992-01-21 AT AT99109196T patent/ATE447016T1/de not_active IP Right Cessation
- 1992-01-21 ES ES99109196T patent/ES2335720T3/es not_active Expired - Lifetime
- 1992-01-21 WO PCT/GB1992/000123 patent/WO1992013069A1/en active IP Right Grant
- 1992-01-21 EP EP92903304A patent/EP0568575B2/de not_active Expired - Lifetime
- 1992-01-21 ES ES92903304T patent/ES2236682T5/es not_active Expired - Lifetime
- 1992-01-21 DE DE0971033T patent/DE971033T1/de active Pending
- 1992-01-21 CA CA002372251A patent/CA2372251A1/en not_active Abandoned
- 1992-01-21 AT AT92903304T patent/ATE286971T1/de not_active IP Right Cessation
- 1992-01-21 CA CA2101774A patent/CA2101774C/en not_active Expired - Lifetime
1995
- 1995-06-05 US US08/464,250 patent/US6300540B1/en not_active Expired - Lifetime
2001
- 2001-12-27 JP JP2001397308A patent/JP3574432B2/ja not_active Expired - Lifetime
2003
- 2003-02-03 US US10/357,935 patent/US20030165958A1/en not_active Abandoned
2004
- 2004-04-30 JP JP2004136760A patent/JP2004261187A/ja active Pending

Also Published As

Publication number	Publication date
ES2236682T5 (es)	2011-03-31
ATE447016T1 (de)	2009-11-15
EP0568575B2 (de)	2010-11-03
CA2372251A1 (en)	1992-08-06
CA2101774A1 (en)	1992-07-22
DE69233468D1 (de)	2005-02-17
US20030165958A1 (en)	2003-09-04
JPH06504441A (ja)	1994-05-26
EP0971033B1 (de)	2009-10-28
EP0971033A2 (de)	2000-01-12
JP2002306195A (ja)	2002-10-22
DK0568575T3 (da)	2005-05-23
DE69233468T3 (de)	2011-05-05
ATE286971T1 (de)	2005-01-15
AU1169492A (en)	1992-08-27
CA2101774C (en)	2011-01-04
AU652997B2 (en)	1994-09-15
JP2004261187A (ja)	2004-09-24
JP3574432B2 (ja)	2004-10-06
EP0568575A1 (de)	1993-11-10
DE971033T1 (de)	2001-05-03
WO1992013069A1 (en)	1992-08-06
US5877015A (en)	1999-03-02
DE69233468T2 (de)	2005-12-22
ES2236682T3 (es)	2005-07-16
DK0971033T3 (da)	2009-12-14
EP0971033A3 (de)	2003-11-12
ES2335720T3 (es)	2010-03-31
US6300540B1 (en)	2001-10-09
DK0568575T4 (da)	2010-12-20
EP0568575B1 (de)	2005-01-12
JP3510244B2 (ja)	2004-03-22

Legal Events

Date	Code	Title	Description
2010-09-23	8363	Opposition against the patent

Publication	Publication Date	Title
DE69233774D1 (de)	2009-12-10	Prüfung und Modell für Alzheimers-Krankheit
DE69839808D1 (de)	2008-09-11	Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
DK0868519T3 (da)	2006-05-08	Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
ES2170104T3 (es)	2002-08-01	Inhibidores de la produccion de proteinas de beta-amiloide.
ATE239797T1 (de)	2003-05-15	Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DK0528932T3 (da)	1996-07-01	Protein associeret med akut pancreatitis og midler til diagnose af akut pancreatitis
NO931889L (no)	1993-11-29	Protease og beslektede DNA-forbindelser
DE69333872D1 (de)	2005-10-20	Sonde zur Diagnose einer ansteckenden Krankheit verursacht durch Escherichia coli, Klebsiella pneumoniae oder Enterobacter cloacae
DK0948604T3 (da)	2004-11-22	Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60133661D1 (de)	2008-05-29	Nachweismittel von patologischen veränderungen des proteins app und ihre verwendungen
DE68925275T2 (de)	1996-08-22	Endotoxin-bindeprotein und dessen verwendung
EP0716591A4 (de)	1998-02-04	Verfahren und Präparat zum Binden von TAU und MAP2c Proteinen
MX9304839A (es)	1994-02-28	Marcador para determinar la inclusion de un bovino en un programa de cria.
ATE315582T1 (de)	2006-02-15	Verwendung von neuregulin-beta als indikator und/oder target
ATE312914T1 (de)	2005-12-15	Rdgb-proteine
DK0592600T3 (da)	2000-04-17	Protein S polypeptider og anvendelse deraf
WO2023173009A3 (en)	2023-10-26	Wild-derived mouse models of alzheimer's disease
DE69519654T2 (de)	2001-05-17	htFIIIA Gen
DE59009360D1 (de)	1995-08-10	Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.